Scientists investigate why brown fat fails with age
NCT ID NCT06627868
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how a molecule called NAD+ affects brown fat, which helps control weight and lowers the risk of diseases like type 2 diabetes. Researchers will compare normal-weight adults and those with obesity to understand why brown fat becomes less active with age. The goal is to find new ways to boost metabolism and prevent obesity-related health problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 68 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2024
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
30 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Willingness to provide informed consent to participate in the BATNAD study * Must be able to read and speak English/Finnish/Swedish well enough to completely understand the instructions and provide informed consent * Age 30-55 (sedentary lifestyle) * BMI = 18-25 kg/m2 (normal-weight subjects) * BMI ≥ 28 kg/m2 and waist circumference more than 100 cm in men and more than 90 cm in women (subjects with obesity) Exclusion Criteria: * Inability to have PET/CT (claustrophobia, metal implants, recent tattoo including metal components, weight \> 200 kg) * Pregnancy and pregnancy related conditions (postpartum/lactation during the last 12 months, or planning to become pregnant soon) * Major alterations in the menstrual cycle (e.g., amenorrhea) * Use of nicotine based products * Hypo- or hyper- thyroidism (medical history, TSH, T3 or T4 levels out of the normal range) * Diabetes mellitus (fasting Hb1Ac \>6.5% or fasting glycaemia\> 7.0 mmol/) * Abnormal oral glucose tolerance test (2h OGTT \> 11.1 mmol/L) * Hypertension (blood pressure \> 160/100 mmHg) * Abnormal cardiovascular status (arrhythmia and/or long QTc in ECG, abnormal cardiac murmur, previous history of cardiovascular disease) * Abnormal coagulopathy (e.g., clotting abnormality) * Malignancies * Immunological, autoimmune and primary/secondary immunodeficiency disorders (including or not any active treatment) * Virus or bacterial infection (both asymptomatic and symptomatic picture) within the 45 days prior to the study start * Vaccination within the 45 days prior to the study start * Episode of fever or major surgery, burns and traumas within the month prior to the study start * Chronic infections requiring chronic antibiotic or anti-viral treatment * Whole blood donation in the last 3 months (\>400 mL of blood) or plans for blood donation during the entire protocol period * Weight change (intentional or not) over the last 6-months more than 5% of body weight, or plan to lose weight during the study * Allergy to lidocaine or epinephrine, or other local anaesthetics * Previous participation to studies where PET or CT method is used * Use of any medication that, in the opinion of local clinician/researcher, would negatively impact or mitigate full participation and completion, or could influence the study results. This especially applies to the use of β or α adrenergic receptors agonists/antagonists (e.g., β-blockers). * Any other cardiovascular, pulmonary, orthopaedic, neurologic, psychiatric or other conditions that, in the opinion of the local clinician/researcher, would preclude participation and successful completion of the protocol, or that would negatively impact or mitigate participation in and completion of the protocol
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obesity are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Turku PET Centre
RECRUITINGTurku, 20520, Finland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Custom knee guides put to the test in obese patients
- A pill for obesity? early human trial puts MDR-001 to the test
- Can a weekly shot help people who still struggle with weight after bariatric surgery?
- Do GLP-1 Weight-Loss drugs change how teens eat and feel?
- Can electrical muscle stimulation boost exercise benefits after menopause?
- Can a cold cloth on the neck calm Post-Surgery nausea?